Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With Fibromyalgia
Trial details
- Registry ID
- NCT02829814
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as Low dose cyclobenzaprine sublingual tablets
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Repeat of: A Study to Evaluate Efficacy and Safety of Sublingual TNX-102 SL Tablet Taken at Bedtime in Patients With FibromyalgiaNCT02829814 | Tonix Pharmaceuticals, Inc. | Phase 3 | Terminated | 2016-09-13Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |